Antiviral Research 104 (2014) 102–109

Contents lists available at ScienceDirect

Antiviral Research journal homepage: www.elsevier.com/locate/antiviral

Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection Eiichi Ogawa a, Norihiro Furusyo a, Eiji Kajiwara b, Hideyuki Nomura c, Kazufumi Dohmen d, Kazuhiro Takahashi e, Makoto Nakamuta f, Takeaki Satoh g, Koichi Azuma h, Akira Kawano i, Yuichi Tanabe j, Kazuhiro Kotoh k, Shinji Shimoda l, Jun Hayashi a,⇑, The Kyushu University Liver Disease Study (KULDS) Group a

Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan c The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu, Japan d Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan e Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan f Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan g Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan h Department of Medicine, Kyushu Central Hospital, Fukuoka, Japan i Department of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan j Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan k Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan l Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan b

a r t i c l e

i n f o

Article history: Received 15 October 2013 Revised 6 January 2014 Accepted 12 January 2014 Available online 23 January 2014 Keywords: Hepatitis C Telaprevir Low-density lipoprotein cholesterol IL28B Pegylated interferon

a b s t r a c t Elevated serum low-density lipoprotein cholesterol (LDL-C) level has been associated with sustained virological response (SVR) by chronic hepatitis C patients treated with pegylated-interferon (PEG-IFN) a and ribavirin (RBV). The aim of this study was to investigate the relation between the baseline LDLC level and the treatment outcome from telaprevir (TVR)-based triple therapy. This prospective, multicenter study consisted of 241 treatment-experienced patients infected with HCV genotype 1b. All received 12 weeks of TVR in combination with 24 weeks of PEG-IFNa2b and RBV. The SVR rate was 81.3% (196 of 241) by intention-to-treat analysis. Higher LDL-C level was strongly associated with SVR (P = 1.3  108). The area under the receiver operating characteristic curve for predicting SVR was 0.78 and the cutoff value for the LDL-C level at baseline was 95 mg/dL. In multivariable logistic regression analysis of predictors of SVR, LDL-C P95 mg/dL (odds ratio [OR] 3.60, P = 0.0238), a-fetoprotein 65.0 ng/mL (OR 5.06, P = 0.0060), prior relapse to PEG-IFNa and RBV (OR 5.71, P = 0.0008), and rapid virological response (HCV RNA undetectable at week 4) (OR 5.52, P = 0.0010) were extracted as independent predictors of SVR. For prior partial and null responders, the SVR rates of the groups with LDL-C P95 mg/ dL were significantly higher than those of the